Literature DB >> 19064200

Functional MR imaging in multiple sclerosis.

Massimo Filippi1, M A Rocca.   

Abstract

A variable effectiveness of reparative and recovery mechanisms following tissue damage is among the factors that might contribute to explaining resolution of symptoms and maintenance of a normal level of function in patients who have multiple sclerosis (MS). The application of functional MR imaging in MS has shown that cortical changes do occur after white matter injury and that these changes can contribute to limiting the clinical outcome of such damage. Conversely, the failure or exhaustion of the adaptive properties of the cerebral cortex with increasing disease duration and burden might be among the factors responsible for the accumulation of fixed neurologic deficits in patients who have MS.

Entities:  

Mesh:

Year:  2009        PMID: 19064200     DOI: 10.1016/j.nic.2008.08.004

Source DB:  PubMed          Journal:  Neuroimaging Clin N Am        ISSN: 1052-5149            Impact factor:   2.264


  14 in total

1.  A randomized, blinded, parallel-group, pilot trial of mycophenolate mofetil (CellCept) compared with interferon beta-1a (Avonex) in patients with relapsing-remitting multiple sclerosis.

Authors:  Elliot M Frohman; Gary Cutter; Gina Remington; Hongjiang Gao; Howard Rossman; Bianca Weinstock-Guttman; Jacqueline E Durfee; Amy Conger; Ellen Carl; Katherine Treadaway; Eric Lindzen; Amber Salter; Teresa C Frohman; Anjali Shah; Angela Bates; Jennifer L Cox; Michael G Dwyer; Olaf Stüve; Benjamin M Greenberg; Michael K Racke; Robert Zivadinov
Journal:  Ther Adv Neurol Disord       Date:  2010-01       Impact factor: 6.570

Review 2.  MR imaging of gray matter involvement in multiple sclerosis: implications for understanding disease pathophysiology and monitoring treatment efficacy.

Authors:  Massimo Filippi; M A Rocca
Journal:  AJNR Am J Neuroradiol       Date:  2009-12-31       Impact factor: 3.825

Review 3.  The role of advanced magnetic resonance imaging techniques in primary progressive MS.

Authors:  Maria A Rocca; Martina Absinta; Massimo Filippi
Journal:  J Neurol       Date:  2011-08-04       Impact factor: 4.849

Review 4.  Imaging resting state brain function in multiple sclerosis.

Authors:  Massimo Filippi; Federica Agosta; Edoardo G Spinelli; Maria Assunta Rocca
Journal:  J Neurol       Date:  2012-10-09       Impact factor: 4.849

5.  The Italian Neuroimaging Network Initiative (INNI): enabling the use of advanced MRI techniques in patients with MS.

Authors:  M Filippi; G Tedeschi; P Pantano; N De Stefano; P Zaratin; M A Rocca
Journal:  Neurol Sci       Date:  2017-03-14       Impact factor: 3.307

Review 6.  Progressive multiple sclerosis and gray matter pathology: an MRI perspective.

Authors:  Matilde Inglese; Niels Oesingmann; Patrizia Casaccia; Lazar Fleysher
Journal:  Mt Sinai J Med       Date:  2011 Mar-Apr

7.  Diffusion tensor imaging based network analysis detects alterations of neuroconnectivity in patients with clinically early relapsing-remitting multiple sclerosis.

Authors:  Yang Li; Valerie Jewells; Minjeong Kim; Yasheng Chen; Andrew Moon; Diane Armao; Luigi Troiani; Silva Markovic-Plese; Weili Lin; Dinggang Shen
Journal:  Hum Brain Mapp       Date:  2012-09-15       Impact factor: 5.038

Review 8.  Relapsing and progressive forms of multiple sclerosis: insights from pathology.

Authors:  Ranjan Dutta; Bruce D Trapp
Journal:  Curr Opin Neurol       Date:  2014-06       Impact factor: 5.710

Review 9.  Measuring Gray Matter and White Matter Damage in MS: Why This is Not Enough.

Authors:  Christian Enzinger; Franz Fazekas
Journal:  Front Neurol       Date:  2015-03-17       Impact factor: 4.003

10.  Functional Magnetic Resonance Imaging of Rats with Experimental Autoimmune Encephalomyelitis Reveals Brain Cortex Remodeling.

Authors:  Stefano Tambalo; Luca Peruzzotti-Jametti; Roberta Rigolio; Silvia Fiorini; Pietro Bontempi; Giulia Mallucci; Beatrice Balzarotti; Paola Marmiroli; Andrea Sbarbati; Guido Cavaletti; Stefano Pluchino; Pasquina Marzola
Journal:  J Neurosci       Date:  2015-07-08       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.